Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide

Vaccine. 2011 Dec 9;30(1):9-13. doi: 10.1016/j.vaccine.2011.10.054. Epub 2011 Oct 30.


The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a serious health concern worldwide that requires new therapeutic approaches that extend beyond the development and use of new antibiotics. In this study, a conformationally biased, response-selective agonist of human C5a, known as EP67, was used to induce host innate immunity as a therapeutic method of reducing CA-MRSA infections. Using a murine model of dermonecrosis we show that EP67 treatment effectively limits CA-MRSA infection by promoting cytokine synthesis and neutrophil influx. In contrast, EP67 was ineffective in reducing lesion formation in C5a receptor (CD88(-/-)) knockout mice, indicating that EP67 activates host innate immunity by engagement of CD88 bearing cells. These results suggest that EP67 may serve as a novel immunotherapeutic for prevention and treatment of CA-MRSA dermal infection.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Complement C5a / agonists
  • Disease Models, Animal
  • Female
  • Immunologic Factors / administration & dosage*
  • Methicillin-Resistant Staphylococcus aureus / immunology*
  • Mice
  • Peptides / administration & dosage*
  • Staphylococcal Skin Infections / drug therapy*
  • Staphylococcal Skin Infections / microbiology*
  • Treatment Outcome


  • Immunologic Factors
  • Peptides
  • Complement C5a